Changes of Gene Expression after Bone Marrow Cell Transfusion in Rats with Monocrotaline-Induced Pulmonary Hypertension by Kim, Kwan Chang et al.
© 2012 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Changes of Gene Expression after Bone Marrow Cell Transfusion 
in Rats with Monocrotaline-Induced Pulmonary Hypertension 
Pulmonary artery hypertension (PAH) causes right ventricular failure and possibly even 
death by a progressive increase in pulmonary vascular resistance. Bone marrow-derived 
mesenchymal stem cell therapy has provided an alternative treatment for ailments of 
various organs by promoting cell regeneration at the site of pathology. The purpose of this 
study was to investigate changes of pulmonary haemodynamics, pathology and expressions 
of various genes, including ET (endothelin)-1, ET receptor A (ERA), endothelial nitric oxide 
synthase (NOS) 3, matrix metalloproteinase (MMP) 2, tissue inhibitor of matrix 
metalloproteinase (TIMP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α in 
monocrotaline (MCT)-induced PAH rat models after bone marrow cell (BMC) transfusion. 
The rats were grouped as the control (C) group, monocrotaline (M) group, and BMC 
transfusion (B) group. M and B groups received subcutaneous (sc) injection of MCT  
(60 mg/kg). BMCs were transfused by intravenous injection at the tail 1 week after MCT 
injection in B group. Results showed that the average RV pressure significantly decreased 
in the B group compared with the M group. RV weight and the ratio of RH/LH+septum 
significantly decreased in the B group compared to the M group. Gene expressions of ET-1, 
ERA, NOS 3, MMP 2, TIMP, IL-6, and TNF-α significantly decreased in week 4 in the B 
group compared with the M group. In conclusion, BMC transfusion appears to improve 
survival rate, RVH, and mean RV pressure, and decreases gene expressions of ET-1, ERA, 
NOS 3, MMP 2, TIMP, IL-6, and TNF-α. 
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ORIGINAL ARTICLE
Cardiovascular Disorders
INTRODUCTION
Pulmonary arterial hypertension (PAH) is difficult to treat and 
is characterized by increased pulmonary arterial pressure, right 
heart dysfunction, lung vascular remodeling, and death (1). 
PAH has been shown to be refractory to most of the conven-
tional pharmacological therapies. Although a number of thera-
pies, including endothelin (ET)-1 antagonists, phosphodiester-
ase inhibitors, and prostanoid have proven useful in decreasing 
pulmonary arterial pressure, the long-term outcome of this con-
dition is still bleak with a low probability of improving exercise 
tolerance and quality of life (2, 3). 
  Gene therapy has been demonstrated to have a beneficial  
effect in experimental models of PAH (4-6). In addition, cell-
based therapies with pulmonary arterial smooth muscle cells 
and endothelial progenitor cells with or without transfection of 
therapeutic genes have a beneficial effect in experimental mod-
els of PAH (7-11).  
  Mesenchymal stem cells (MSCs), also known as marrow stro-
mal cells, are a type of adult stem cells derived from the bone 
marrow (12). Stem cell based therapy has received attention as 
a possible alternative to organ transplantation, owing to the abil-
ity of stem cells to repopulate and differentiate at the engrafted 
site. Stem cell therapy may constitute a new treatment modality 
for patients with PAH (4, 13).
  However, literature is rare on changes of gene expression after 
MSCs in the treatment of PAH. Although previous studies show 
that MSCs are capable of differentiating into pulmonary lineage 
cells in an injured lung, there is little information on changes of 
gene expressions after administration of MSCs in monocrota-
line (MCT)-treated rats (14-16).  
  MCT has been reported to damage the endothelium of pul-
monary arteries and induce progressive pulmonary hyperten-
sion in rats after a single subcutaneous injection (17). Also, it has 
been reported to impair endothelium-dependent responses in 
the isolated lung arteries and rat lung (18). 
  The purpose of this study was to investigate changes of pul-
monary hemodynamics, pathology and expressions of genes, 
including endothelin (ET)-1, ET receptor A (ERA), endothelial 
nitric oxide synthase (NOS) 3, matrix metalloproteinase (MMP) 
2, tissue inhibitor of matrix metalloproteinase (TIMP), interleu-
kin (IL)-6 and tumor necrosis factor (TNF)-α in MCT-induced Kim KC, et al.  •  Gene Expression Changes after Bone Marrow Cell Transfusion in Rats
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PAH rat model after bone marrow cell (BMC) transfusion.
MATERIALS AND METHODS
Materials
Six-week-old male Sprague-Dawley rats, weighing approximate-
ly 250-300 g, were used for this study. All rats were housed in 
climate-controlled conditions with 12 hr light exposure: a 12 hr 
dark cycle, and had free access to chow food and water.
  Pulmonary hypertension was induced by subcutaneous (sc) 
injection of 60 mg/kg MCT (Sigma Chemicals, St. Louis, MO, 
USA) dissolved in 0.5 N HCl solution. The rats were grouped as 
follows: control group (n = 12), which received sc injection of 
saline; M group (n = 12), which received sc injection of MCT; 
BMC transfusion (B) group (n = 12), in which BMC (2 ×10
7 cells) 
were transfused by intravenous injection at the tail 1 week after 
MCT injection. The rats were sacrificed in weeks 2 and 4. Lung 
tissues were removed and immediately frozen at -70°C for en-
zyme analysis, post-fixed in 10% formalin, and processed rou-
tinely for paraffin embedding. All protocols were approved by 
the Institutional Animal Care and Use Committees of the School 
of Medicine of Ewha Womans University (approval No. ESM 
11-0169).
Organ weights
The rats were weighed and observed for general appearance 
during the study period. The animals were sacrificed at the sched-
uled time, and the hearts and lungs were rapidly removed. The 
wet weights of the right ventricle (RV), left ventricle and septum 
(LV+S) were measured and the ratio of organ weight to body 
weight was calculated. The RV to LV+S ratio, (RV/[LV+S]) was 
used as an index of RVH. 
Measurement of mean right ventricular pressure (RVP)
The animals were placed in the supine position and instrument-
ed with an arterial pressure line (Physiological Pressure Trans-
ducer, MLT1199; AD Instruments, Oxfordshire, UK). Hemody-
namic parameters were recorded at baseline and in weeks 2 
and 4. The catheter was placed in the RV to measure mean RVP. 
Morphometric analysis of pulmonary arteries
Lung tissue was fixed with 10% buffered formalin with gentle 
perfusion through the trachea for 24 hr and then embedded in 
paraffin. Three μm -thick sections were stained with Victoria 
blue to evaluate histopathologic changes of pulmonary blood 
vessels. More than 20 images of pulmonary arterioles (50-160 μm 
diameters) per tissue section at a magnification of 400 × were 
captured using a microscopic digital camera and analyzed us-
ing an image analysis program (analySIS, Olympus Soft Imag-
ing Solutions, Singapore). The external diameter (D), across the 
smallest diameter, and the medial wall thickness between the 
internal and external elastic lamina of two sides of muscular  
arteries (M1 and M2) were measured. The percentage of wall 
thickness was calculated as follows: % wall thickness = (M1 + 
M2)/D × 100 (Fig. 1). In addition, the number of muscular ar-
teries accompanied by respiratory bronchioli and present in al-
veolar wall were counted. A total of 20 randomly selected mi-
croscopic fields per tissue section at a magnification (200 ×) 
were assessed.
RNA extraction and cDNA synthesis
Total RNA was extracted by using TRIzol Reagent
TM (Invitrogen, 
Carlsbad, CA, USA), according to the Trizol method protocol 
and resuspended in diethyl pyrocarbonate water. The final RNA 
amount was spectrophotometrically determined at 260/280 nm. 
Quality was assessed as the absence of smear of 18S and 28S 
bands analyzed by means of Bio analyzer 2100 (Agilent tech-
nologies, CA, USA). RNA samples were stored at -70°C prior to 
usage. cDNAs were synthesized by 1 μg of total RNA, according 
to the manufacture’s protocol (Hight Capacity RNA-to-cDNA 
kit, Appllied Biosystems, CA, USA).
Gene expression analysis by real time reverse transcription-
polymerase chain reaction (RT-PCR)
Real-time quantitative PCR was performed in triplicate in 384-
well plates. A 384-well high-throughput analysis was performed 
by using the ABI Prism 7900 Sequence Detection System Soft-
ware (Applied Biosystems) and white colored 384-well plates 
(ABgene, Hamburg, Germany) for intensification of the fluores-
cent signals by a factor of three. The system operated using a 
thermal cycler and a laser that is directed via fiber optics to each 
of the 384 sample wells. The fluorescence emission from each 
sample was collected by a charge-coupled device-camera and 
the quantitative data were analyzed using the Sequence Detec-
M1
M2
D
Fig. 1. Morphometric analysis of pulmonary arteries. The external diameter (D), across 
the smallest diameter, and the medial wall thickness between the internal and exter-
nal elastic lamina of two sides of muscular arteries (M1 and M2) were measured. The 
percentage of wall thickness was calculated as follows: % wall thickness = (M1 + M2)/ 
D × 100 (H&E staining, × 400).Kim KC, et al.  •  Gene Expression Changes after Bone Marrow Cell Transfusion in Rats
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tion System Software (SDS version 2.0, Applied Biosystems). 
Reaction mixtures contained 10 pM/μL of each primer and 2X 
SYBR Green PCR Master Mix (Applied Biosystems), which in-
cludes the HotStarTaqt DNA-Polymerase in an optimized buf-
fer, the dNTP mix (with dUTP additive), the SYBRs Green I fluo-
rescent dye, and ROX dye as a passive reference. Each of the 384-
well real-time quantitative PCR plates included serial dilutions 
(1, 1/2, and 1/4) of cDNA, which were used to generate relative 
standard curves for genes.
  The resulting first-strand of cDNA were normalized by the 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene. 
The normalized cDNA was used for the PCR procedure as a tem-
plate. The specific primers for rat ET-1 were 5´- TCTCGGAGAG- 
CAGAGACACA -3´ (forward) and 5´- TGGACTTTGGAGTTTC-
TCCCT -3´ (reverse); 
  The specific primers for ERA were 5´- CACAGGCTTCAGT-
GTGCATT -3´ (forward) and 5´- CAACACAGGCCCTTAGCTTC- 
3´ (reverse); 
  The specific primers for NOS 3 were 5´- CTGCGGTGATGT-
CACTATGG -3´ (forward) and 5´- AAATGTCCTCGTGGTAGG- 
GT -3´ (reverse); 
  The specific primers for MMP 2 were 5´- AAGAGGCCTGGT-
TACCCTGT -3´ (forward) and 5´- AAGTAGCACCTGGGAGGGAT- 
3´ (reverse); 
  The specific primers for TIMP were 5´- GACCTATAGTGCTG-
GCTGTG -3´ (forward) and 5´- GATCGCTCTGGTAGCCCTTCT- 
3´ (reverse). 
  The specific primers for IL-6 were 5´- CCG GAG AGG AGA 
CTT CAC AG -3´ (forward) and 5´- GATCGCTCTGGTAGCCC- 
TTCT -3´ (reverse); 
  The specific primers for TNF-α were 5´- GAC AGT TGA TTT 
CTG GGC CCT TT -3´ (forward) and 5´- CCA CTG TTC TGT 
GCT CC -3´ (reverse) (Fig. 2).
  All primers were amplified using the same conditions. Ther-
mal cycling conditions were 50°C for 2 min and 95°C for 10 min 
followed by 40 cycles of 95°C for 30 sec and 60°C for 30 sec, 72°C 
for 30 sec. In order to exclude the presence of unspecific prod-
ucts, a melting curve analysis of products was performed rou-
tinely after finishing amplification by a high-resolution data 
collection during an incremental temperature increase from 
60°C to 95°C with a ramp rate of 0.21°C/sec. We then converted 
real-time PCR cycle numbers to gene amounts (ng) on the ba-
sis of the equation. The real-time PCR analysis was performed 
on an Applied Biosystems Prism 7900 Sequence Detection Sys-
tem (PE Applied Biosystems).
Western blot analysis
The tissue was homogenized in 10 mM Tris HCl buffer, pH 7.4 
containing 0.5 mM EDTA, pH 8.0, 0.25 M sucrose, 1 mM PMSF, 
1 mM Na4VO3 and a protease inhibitor cocktail (Roche-Boeh-
ringer-Mannheim, IN, USA). After centrifugation, the superna-
tant was subjected to sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE). Samples equivalent to 25 μg of 
protein content were loaded and size-separated in 10% SDS-
PAGE. The proteins on the acrylamide gel were transferred to a 
polyvinylidene difluoride membrane (Millipore, Bedford, MA, 
USA) at 400 mA in a transfer buffer containing 25 mM Tris and 
192 mM glycine, pH 8.4. The PVD membranes was blocked in 
TBS with 5% non-fat dry milk at room temperature for 1 hr in 
0.1% TBS-Tween 20 and incubated with the specific primary 
antibodies, including ET-1, ERA, NOS 3, MMP 2, TIMP, IL-6, and 
TNF-α (Cell Signaling Technology Inc., Danvers, MA, USA) and 
GAPDH (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), 
at 4°C overnight. The membrane was incubated with horserad-
ish peroxidase-conjugated secondary antibody (Cell Signaling 
Technology Inc., Danvers, MA, USA) for 1 hr at room tempera-
ture. After washing, the membrane was visualized by a chemi-
luminescence reaction using an ECL-detection kit system (Am-
ersham Pharmacia Biotechnology, CA, USA). The cell lysate 
from the solubilized tissue was mixed with the Pierce BCA re-
agents (Pierce, Rockford, IL, USA) and incubated for 30 min. 
The protein content was quantified with a Molecular Devices 
ELISA reader (Amersham Pharmacia Biotechnology, Sunny-
vale, CA, USA) at 562 nm based on the bovine serum albumin 
standard curve. 
Cell preparation 
To isolate donor BMCs, Sprague-Dawley rats were sacrified by 
cervical dislocation, and their limbs were subsequently re-
moved. Bone marrow was flushed from the medullary cavities 
of both the femurs and tibias with RPMI-1640 medium (Gibco 
BRL, Carlsbad, CA, USA) using a 25-gauge needle. For BM-MSC 
isolation, C3H/he BMC were plated at a density of 2 × 10
7/mL/
cm
2, and cultured in complete MesenCult Basal Medium for 
Murine Mesenchymal Stem Cells (Stem Cell Technologies, 
Vancouver, Canada) containing mesenchymal stem cell stimu-
Fig. 2. The RT-PCR products from the transcripts of IL-6, TNF-α, ET-1, ERA, NOS3, 
MMP2, TIMP and TIMP were 132 bp, 113 bp, 156 bp, 118 bp, 140 bp, 137 bp, and 
133 bp respectively. TNF, tumor necrosis factor; ET-1, endothelin-1; ERA, endothelin 
receptor A; NOS-3, endothelial nitric oxide synthase; MMP 2, matrix metalloprotein-
ase 2; TIMP, tissue inhibitor of matrix metalloproteinases; IL, interleukin.  Kim KC, et al.  •  Gene Expression Changes after Bone Marrow Cell Transfusion in Rats
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latory supplements, 100 U/mL penicillin and 100 μg/mL strep-
tomycin (Invitrogen Life Technologies) at 37°C in a 5% CO2 at-
mosphere. At 48 hr, the non-adherent cells were removed by 
washing with 1 × PBS, and fresh medium was then added. The 
medium was changed weekly. When the culture was near con-
fluence, the monolayer cells were washed twice with 1 × PBS, 
and were incubated for 2-3 min at 37°C with a 0.25% trypsin so-
lution containing 0.01% EDTA (Invitrogen Life Technologies). 
Trypsin was neutralized by the addition of fresh complete me-
dium. The resulting suspension was then expanded by plating 
it onto a new culture flask.
Statistical analysis 
Results were expressed as the mean ± standard deviation. An 
unpaired two-tailed t-test and Mann-Whitney test were used to 
compare the three groups and a P value < 0.05 was considered 
statistically significant. SPSS 12.0 for Windows (SPSS, Chicago, 
IL, USA) was used for all statistical analyses.
RESULTS
Effect of bone marrow cell on survival 
There were no deaths in the control group. Four-week survival 
was 67% in the MCT group; and the survival was significantly 
increased to 87.5% in the B group (P < 0.05). 
Changes of total weight and heart weight
Total weight of rats significantly decreased in the M group com-
pared with the C group in week 4. The RV weight significantly 
increased in the M group in weeks 2 and 4. The RV weight sig-
nificantly decreased in the B group compared with the M group 
in weeks 2 and 4. Also, LV and septum (S) weight decreased in 
the M group in week 4, but no significant decrease was observed 
in the B group. In week 4, the RV/LV+S weight significantly de-
creased in the B group compared with the M group (Table 1).
Measurement of right ventricular pressure
The mean right ventricular pressure (RVP) significantly decreased 
Table 1. Changes in body weight, right ventricle, left ventricle, RV/LV+septum and lung in each group 
Group Week Body weight (g) RV (g) LV+ S (g) RV/LV+S Lung (g)
C 2
4
341.3 ± 9.6
406.3 ± 32.0
0.21 ± 0.01
0.23 ± 0.04
0.70 ± 0.70
0.84 ± 0.09
0.31 ± 0.03
0.28 ± 0.04
1.3 ± 0.07
1.44 ± 0.17
M 2
4
329.4 ± 10.2
317.3 ± 10.6*
0.27 ± 0.04*
0.54 ± 0.06*
0.73 ± 0.66
0.68 ± 0.07*
 0.53 ± 0.04*
 0.79 ± 0.04*
2.04 ± 0.17
1.89 ± 0.24*
B 2
4
302.1 ± 21.5
312.3 ± 35.8
0.22 ± 0.03
†
0.46 ± 0.04
†
0.66 ± 0.68
0.74 ± 0.04
 0.33 ± 0.06
  0.64 ± 0.06
†
1.77 ± 0.24
2.11 ± 0.1
*P < 0.05 vs the corresponding value in the C group; 
†P < 0.05 vs the corresponding value in the M group. RV, right ventricle; LV, left ventricle; C, control; M, monocrotaline; B, 
bone marrow cell. 
Table 2. Mean right ventricular pressure (mmHg) in each group
Week C group (n = 12) M group (n = 12) B group (n = 12)
2 11.7 ± 0.6 34.8 ± 7.4* 15.4 ± 3.8
† 
4 11.5 ± 0.7  42.3 ± 13.0*  14.8 ± 3.6
†
*P < 0.05 vs the corresponding value in the C group; 
†P < 0.05 vs the corresponding 
value in the M group. C, control; M, monocrotaline; B, bone marrow cell. 
Table 3. Ratio of medial wall thickness of pulmonary artery in each group (%)
Week C group (n = 12) M group (n = 12) B group (n = 12)
2 17.5 ± 6.6 38.8 ± 1.9* 29.3 ± 5.2
†
4 19.9 ± 8.6 40.2 ± 5.4* 35.7 ± 5.7
*P < 0.05 vs the corresponding value in the C group; 
†P < 0.05 vs the corresponding 
value in the M group. C, control; M, monocrotaline; B, bone marrow cell. 
Fig. 3. Photographs of peripheral pulmonary arteries in three groups (Victoria blue staining × 400). The medial layer of the pulmonary arterioles was progressively thickened 
after monocrotaline injection. The medial wall thickness of the M injection was significantly attenuated in B group. C, control; M, monocrotaline; B, bone marrow cell. 
C group M group B groupKim KC, et al.  •  Gene Expression Changes after Bone Marrow Cell Transfusion in Rats
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in the B group compared with the M group in week 2 (34.8 ± 7.4 
mmHg vs 15.4 ± 3.8 mmHg, P < 0.05) and in week 4 (42.3 ± 13.0 
mmHg vs 14.8 ± 3.6 mmHg, P < 0.05) (Table 2).
Histologic study
The predominant changes in pulmonary vasculature included 
the development of medial wall thickening in the pulmonary 
arterioles in the M group compared with the C group in weeks 
2 and 4. In contrast, medial wall thickness of the pulmonary   
arterioles appeared to be thin in the B group in week 4 (Fig. 3).
Medial wall thickness of the pulmonary artery
The ratio of medial thickness to the external diameter of the pul-
monary artery in the M group significantly increased compared 
with C group in week 2 (38.8 ± 1.9% vs 17.5 ± 6.6%, P < 0.05) 
and in week 4 (40.2 ± 5.4% vs 19.9 ± 8.6%, P < 0.05). In the B 
group, the ratio of medial thickening of the pulmonary artery 
was significantly decreased compared with the M group in 
week 2 (29.3 ± 5.2% vs 38.8 ± 1.9%, P < 0.05) (Table 3).
The number of muscular pulmonary arteriole
The number of muscular pulmonary arterioles increased in the 
M group compared with the C group in week 2 (1.5 ± 0.1 vs 0.8 ±  
0.2, P < 0.05) and in week 4 (2.0 ± 0.1 vs 0.9 ± 0.2, P < 0.05). The 
number of muscular pulmonary arterioles significantly de-
creased in the B group compared with the M group in week 4 
(1.4 ± 0.3 vs 2.0 ± 0.1, P < 0.05) (Table 4). 
Gene expressions of endothelin-1 in rat lungs
Gene expressions of ET-1 in the M group were higher than in 
the C group in weeks 2 and 4. Gene expressions of ET-1 in the B 
group were lower than in the M group in week 4 (Fig. 4A). 
Gene expressions of endothelin receptor A in rat lungs
The ERA gene expressions significantly increased in the M 
group more than in the C group in weeks 2 and 4. However, 
gene expressions of ERA significantly decreased in the B group 
than in the M group in week 4 (Fig. 4B).
Gene expressions of endothelial nitric oxide synthase in 
rat lungs
Gene expressions of NOS 3 significantly increased in the M group 
Fig. 4. Gene expressions of ET-1. (A) ERA, (B) NOS3, (C) MMP2, (D) after bone marrow cell transfusion. *P < 0.05 vs the corresponding value in the C group; 
†P < 0.05 vs the 
corresponding value in the M group. C, control; M, monocrotaline; B, bone marrow cell; ET-1, endothelin-1; ERA, endothelin receptor A; NOS3, nitric oxide synthase-3; MMP2, 
matrix metallo proteinase2.
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Table 4. Number of muscular intra-acinar arteries in each group 
Week C group (n = 12) M group (n = 12) B group (n = 12)
2 0.8 ± 0.2 1.5 ± 0.1*  1.4 ± 0.2
4 0.9 ± 0.2 2.0 ± 0.1*   1.4 ± 0.3
†
*P < 0.05 vs the corresponding value in the C group; 
†P < 0.05 vs the corresponding 
value in the M group. C, control; M, monocrotaline; B, bone marrow cell. Kim KC, et al.  •  Gene Expression Changes after Bone Marrow Cell Transfusion in Rats
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than in the C group in weeks 2 and 4. The gene expressions of 
NOS 3 significantly decreased in the B group than in the M group 
in week 4 (Fig. 4C).
Gene expressions of matrix metalloproteinases 2 in rat 
lungs
Gene expressions of MMP 2 significantly increased in the M 
group than in the C group in weeks 2 and 4. In week 4, the gene 
expressions of MMP 2 significantly decreased in the B group 
compared to the M group (Fig. 4D).
Gene expressions of tissue inhibitor of matrix 
metalloproteinases in rat lungs
The gene expressions of TIMP significantly increased in the M 
group than in the C group in weeks 2 and 4. The gene expres-
sions of TIMP significantly decreased in the B group than in the 
M group in week 4 (Fig. 5A).
Gene expressions of IL-6 in rat lungs
The gene expressions of IL-6 significantly increased in the M 
group than in the C group in weeks 2 and 4. The gene expres-
sions of IL-6 significantly decreased in the B group than the M 
group in week 4 (Fig. 5B).
Gene expressions of TNF-α in rat lungs
The gene expressions of TNF-α significantly increased in the M 
group than in the C group in weeks 2 and 4. The gene expres-
sions of TNF-α significantly decreased in the B group compared 
with the M group in week 4 (Fig. 5C).
DISCUSSION
Monocrotaline (MCT), a pyrrolizidine alkaloid derived from 
Crotalaria spectabilis, causes a pulmonary vascular syndrome 
in rats characterized by proliferative pulmonary vasculitis, PAH 
and cor pulmonale. In rats with MCT-induced PAH, the eleva-
tion of pulmonary arterial pressure correlates with a thickening 
of the medial wall in small pulmonary arteries and arterioles 
due to the proliferation of vascular smooth muscle cells (17, 19, 
20). We have demonstrated pathologic finding and changes of 
gene expressions in MCT model of PAH in our previous studies 
(17, 19, 20) and confirmed in the present study. The evidence 
includes the following data: 1) RV and the ratio of RV to LV+S 
progressively increased in weeks 2 and 4; 2) the right ventricu-
lar pressure (RVP) progressively increased in the M group com-
pared with the C group in weeks 2 and 4; 3) medial thickening 
in the pulmonary arterioles and an increased number of intra-
acinar muscular arteries were noted in the M group in weeks 2 
and 4; 4) gene expressions of ET-1, ERA, NOS 3, MMP 2, TIMP, 
IL-6, and TNF-α significantly increased in the M group in weeks 
2 and 4. The pathologic findings were consistent with other re-
sults which showed a significant rise of pulmonary blood pres-
sure and apparent RVH after MCT injection (21, 22). 
  Utilizing this well established model of PAH, the present study 
Fig. 5. Gene expressions of TIMP. (A) IL-6, (B) TNF-α, (C) after bone marrow cell 
transfusion. *P < 0.05 vs the corresponding value in the C group; 
†P < 0.05 vs 
the corresponding value in the M group. C, control; M, monocrotaline; B, bone 
marrow cell; TIMP, tissue inhibitor of matrix metalloproteinases; IL-6, Interleukin-6; 
TNF, tumor necrosis factor.
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showed that an intravenous administration of BMC attenuated 
the MCT-induced PAH in the rat model. BMC treatment atten-
uated average RVH in weeks 2 and 4 and RV weight in weeks 2 
and 4 in the BM group compared to the M group. RH/LH+S   
ratio significantly lowered in weeks 2 and 4. After BMC admin-
istration, medial wall thickness of the pulmonary arteries sig-
nificantly decreased in week 2 and the number of muscular pul-
monary arterioles significantly decreased in week 4 compared 
with the M group. Expressions of various genes, including ET1, 
ERA, NOS 3, MMP 2, TIMP, IL-6, and TNF-α significantly de-
creased in the B group compared to the M group in week 4. 
Changes of several gene expressions are more sensitive than 
those of pulmonary pathology (19). Our data is consistent with 
reports that BMC transplantation reduces the development of 
PAH by increasing vascular beds in pulmonary circulation (23). 
Although previous studies showed that MSCs are capable of 
differentiating into pulmonary lineage cells in the injured lung, 
there was little information about the effect of administered 
MSCs on pulmonary vascular resistance and endothelium-de-
pendent responses in MCT-treated rats (14-16). Therefore, our 
data provide a strong rationale that stem cell therapy may con-
stitute a new treatment modality for patients with PAH (13). 
  There are several possible mechanisms contributing to the 
efficacy of our therapeutic approach (23). MSCs are reported to 
have the tendency to home in on the damaged locations (24). 
MSCs may filter through the lungs and engraft at the sites of lung 
parenchymal or vascular damage. MSCs have been reported to 
lodge in the pulmonary circulation in PAH models by intrave-
nous administration (25). In addition, MSCs are known to rap-
idly multiply and survive even under low-serum conditions (26). 
Thus, some have suggested that MSCs have the pluripotent abil-
ity to become endothelial progenitor cells and other cell lineag-
es (27). Therefore, MSCs could home in to the lesion and regen-
erate to increase the microvascular beds, eventually leading to 
a decrease in vascular resistance. 
  Transplanted MSCs may repair injured vascular endotheli-
um by an action involving the release of factors that improve 
endothelial function or stimulate vascular growth in the MCT-
injured lung (11, 12, 28). Significantly decreased ET-1, ERA, and 
eNOS gene expressions suggest that BMC improved endotheli-
al cell function.
  The release of growth factors or cytokines has been described 
when stem cells are transplanted into the microenvironment of 
injured tissue and serve as biological catalysts for tissue repair 
and regeneration (28). In our study, IL-6 and TNF-α gene ex-
pressions significantly decreased in 4 week.
  Baber et al. (4) published that the intratracheal injection of 
3 × 10
6 MSCs two weeks after administration of MCT attenuat-
ed the rise in pulmonary arterial pressure and pulmonary vas-
cular resistance when responses were evaluated in week 5. These 
data suggested that the decrease in pulmonary vascular resis-
tance and improvement in response to acetylcholine an endo-
thelium-dependent vasodilator in MCT treated rats may result 
from a paracrine effect of the transplanted MSCs in lung paren-
chyma, which improves vascular endothelial function in the 
MCT-injured lung.  
  In our study, gene expressions of ET-1, ERA, NOS 3, MMP 2, 
TIMP, IL-6, and TNF- α had significantly increased in the M group 
in weeks 2 and 4 significantly decreased in week 4 in the B group 
compared with the M group. These may have played a major 
role in the observed efficacy for PAH.  
  The optimal dose and frequency of BMC transfusion is not 
determined yet. Various timing and doses of BMC transfusion 
were employed by many authors (4, 13, 23). An overdose of 
MSCs may also lead to pulmonary embolism and rapid mortal-
ity (23). Therefore, the amount of administered MSCs is a criti-
cal parameter. To address this problem, MSCs overexpressing 
eNOS may be preferable over MSCs alone in the treatment of 
RV impairment caused by PAH because eNOS can reduce the 
amount of administered cells required (23). Kanki-Horimoto et 
al. (23) evaluated RV hypertrophy and the elevation of RV sys-
tolic pressure three weeks after MCT administration. Intrave-
nous implantation of MSCs/eNOS ameliorated PAH-related RV 
impairment and survival time. The gene-transduced MSCs not 
only regenerated endothelial cells thereby increasing the vas-
cular beds of pulmonary arteries but enhanced the secretion of 
NO from the endothelial cells. These processes are thought to 
decrease the constriction of pulmonary arteries and their resis-
tance, resulting in a reduction in PAH (23). 
  Different modes of administration of stem cells, including in-
travenous (23), intratracheal (4) and direct implantation of cells 
into the lungs (11) have been investigated. In our study, 2 × 10
7 
BMC were transfused by intravenous injection one week after 
MCT injection. The rats were sacrificed in weeks 2 and 4 to as-
sess the response of BMC transfusion. In our pilot study, intra-
tracheal administration of BMC led to hypoxia. We believe that 
the intravenous route of administration is a safe and effective 
method of cell injection (13). Survival rate was much improved 
after BMC transfusion. 
  Umar et al. (13) reported that rats were treated with 10
6 MSCs 
intravenously on day 14 and MSCs were obtained from donor 
rats with PAH 28 days after MCT. On day 28, the RV function of 
recipient rats was assessed, followed by isolation of the lungs 
and heart. The application of MSCs from donor rats with PAH 
reduced RV pressure overload, RV dysfunction and lung pathol-
ogy in recipient rats with PAH. These results suggest that autol-
ogous MSC therapy may alleviate cardiac and pulmonary symp-
toms in PAH patients (13). 
  The limitations of our study are as follows. First, no histo-
chemical analysis was performed in this study. Hence, whether 
regenerative responses including recruitment and homing of 
implanted MSCs occurred in the pulmonary microvasculature Kim KC, et al.  •  Gene Expression Changes after Bone Marrow Cell Transfusion in Rats
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is unclear. Second, whether several factors other than pulmo-
nary arterial pressure and RV hypertrophy contribute to the pro-
longation of survival time has not been established. Third, sam-
ple size is small and the follow-up duration is relatively short. 
Future studies with larger sample size and a longer follow-up 
duration will be required to determine the appropriate amount 
of BMC count, frequency and time interval required for PAH 
treatment.
  In conclusion, BMC transfusion improves survival rate, RVH, 
and mean RVP, and decreases gene expressions of ET-1, ERA, 
NOS 3, MMP 2, TIMP, IL-6 and TNF-α in the MCT-induced PAH 
rat model. 
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